Folds (106) higher expression of EP4 is reported in cervical cancer compared with normal controls.4 Moreover, EP4, unlike other prostanoid receptors, associates with multiple signaling pathways involved in carcinogenesis.9 In the present study we demonstrate EP4 prostanoid receptor as a potential therapeutic target in cervical cancer using GW627368X, a highly selective, competitive EP4 antagonist.10 We explored the interactive signaling between EP4 prostanoid receptor and the epidermal growth factor receptor (EGFR). This evidence concerns the gene EGFR and cervical cancer.